Brimapitide: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •1 community protocols documented
- •Evidence level: Anecdotal Reports
- •Based on 5 community reports
- •Stacking patterns detailed below
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Administration Complexity | Clinical trials administer brimapitide as a single intratympanic injection (into the middle ear) in a biocompatible gel formulation for sudden sensorineural hearing loss. Other studies used subconjunctival injection for ocular inflammation. | There is essentially no community self-administration of brimapitide. The intratympanic and subconjunctival routes require medical professionals and specialized equipment. | high Brimapitide's routes of administration (intratympanic, subconjunctival) are not amenable to self-administration, explaining the absence of community protocols. |
| Indication Specificity | Phase III trials targeted acute inner ear hearing loss (idiopathic sudden sensorineural hearing loss) and post-cataract surgery inflammation. Research programs also explore nephrology and Alzheimer's disease. | Community awareness of brimapitide is primarily academic. Discussion focuses on its JNK inhibitor mechanism and potential future applications rather than current self-use. | moderate Brimapitide represents a pipeline peptide with clinical trial data but no practical community self-use pathway. |
Compare these community approaches with published research findings.
Community Protocols
No Established Community Protocol
Niche- Route
- Intratympanic
- Dose
- 0.4-0.8 mg
- Frequency
- Single administration
- Duration
- Single dose
Based on clinical trial dosing for sudden hearing loss; requires medical administration; no self-use protocols exist
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 5+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/Peptides|Brimapitide (XG-102) discussions and JNK inhibitor research(accessed 2026-02-16)
- ClinicalTrials.gov|Brimapitide Phase III clinical trial for hearing loss(accessed 2026-02-16)
Community Evidence Overview#
This page presents information about Brimapitide (XG-102) in the context of community awareness and discussion. This is not clinical evidence and should not be used as medical guidance.
Brimapitide is unique among peptides in this directory in that it has substantial clinical trial data (Phase III) but essentially no community self-use. This is because its routes of administration (intratympanic injection for hearing loss, subconjunctival injection for ocular inflammation) require medical professionals and specialized equipment, making self-administration impractical and unsafe.
Why There Are No Community Protocols#
Unlike most peptides in the community space, brimapitide cannot be self-administered through common routes like subcutaneous injection. The intratympanic route involves injecting a gel formulation directly into the middle ear, which must be performed by an otolaryngologist. Similarly, subconjunctival injection requires ophthalmological expertise.
Community Discussion Context#
Community awareness of brimapitide is primarily academic, focused on:
- Its mechanism as a JNK inhibitor and potential neuroprotective applications
- Clinical trial results showing efficacy for sudden hearing loss
- Future potential if alternative routes of administration are developed
- The broader category of cell-penetrating peptides in therapeutic development
Clinical Trial Evidence#
While community self-use data is absent, brimapitide has some of the strongest clinical evidence among peptides listed in this directory:
- Phase III trials demonstrated efficacy for sudden sensorineural hearing loss
- Low-dose brimapitide showed significantly better hearing outcomes vs placebo
- Single-dose administration (intratympanic gel) provides sustained local drug delivery
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Brimapitide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.